Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
Top Cited Papers
- 14 November 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (22) , 5581-5590
- https://doi.org/10.1158/1078-0432.ccr-10-0851
Abstract
Purpose: Anaplastic lymphoma kinase (ALK) rearrangements, associated with sensitivity to an experimental ALK/MET inhibitor, occur in 3% to 5% of non–small cell lung cancers. Intratumoral fluorescence in situ hybridization (FISH) heterogeneity has been reported. We explored the heterogeneity basis, the requirements for accurately determining ALK FISH positivity, and the effect of enriching the tested population using clinical and molecular factors. Experimental Design: Lung cancer patients were screened by ALK and MET FISH and for EGFR and KRAS mutations. Results: Thirteen ALK-positive cases were identified from 73 screened patients. Gene copy number increases occurred together with classic rearrangements. All positive cases were adenocarcinomas, 12 were EGFR/KRAS wild-type, and 1 had a coexistent EGFR exon 20 mutation. No association with MET amplification occurred. ALK positivity was associated with P = 0.0004). Among adenocarcinomas, without KRAS or EGFR mutations, with ALK FISH positivity was heterogeneous, but mean values in tumor areas from ALK-positive patients (54% of cells; range, 22-87%) were significantly higher than in adjacent normal tissue or tumor/normal areas from ALK-negative patients (mean, 5-7%). Contiguous sliding field analyses showed diffuse heterogeneity without evidence of focal ALK rearrangements. One hundred percent sensitivity and specificity occurred when four or more fields (∼60 cells) were counted. Conclusions: Intratumoral ALK FISH heterogeneity reflects technique, not biology. The clinical activity of ALK/MET inhibitors in ALK-positive patients probably reflects ALK, but not MET, activity. Prescreening by histology, EGFR/KRAS mutations, and smoking status dramatically increases the ALK-positive hit rate compared with unselected series. Clin Cancer Res; 16(22); 5581–90. ©2010 AACR.Keywords
This publication has 27 references indexed in Scilit:
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 2009
- Anaplastic lymphoma kinase: signalling in development and diseaseBiochemical Journal, 2009
- Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer PatientsJournal of Clinical Oncology, 2009
- EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung TissuesThe American Journal of Pathology, 2009
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences, 2007